Abstract
Background Cardiovascular disease (CVD) is a leading cause of health loss and health sector economic burdens in high-income countries. Unemployment is associated with increased risk of CVD, and so there is concern that the economic downturn associated with the COVID-19 pandemic will increase the CVD burden.
Aims This modeling study aimed to quantify health loss, health cost burden and health inequities among people with CVD due to additional unemployment caused by COVID-19 pandemic-related economic disruption in one high-income country: New Zealand (NZ).
Methods We adapted an established and validated multi-state life-table model for CVD in the national NZ population. We modeled indirect effects (ie, higher CVD incidence due to high unemployment rates) for various scenarios of pandemic-related unemployment projections.
Results We estimated the CVD-related heath loss in NZ to range from 23,300 to 36,900 HALYs (health-adjusted life years) for the different unemployment scenarios. Health inequities for Māori (Indigenous population) were 3.7 times greater compared to non-Māori (49.9 vs 13.5 HALYs lost per 1000 people).
Conclusions and policy implications Unemployment due to the COVID-19 pandemic is likely to cause significant health loss and health inequities from CVD in this high-income country. Prevention measures should be considered by governments to reduce this risk, including job creation programs and measures directed towards CVD prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NN and NW were supported by the Health Research Council of NZ (grant 10/248 and grant 16/443).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval for use of anonymized administrative data as part of the BODE3 Programme has been granted by the Health and Disability Ethics Committees (reference number H13/049).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Sharing of anonymized cohort data with other researchers or official agencies of the other epidemiological and costing data will generally be possible on request from the authors (pending approval of the relevant official agencies).
